Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity.
Dose volume histogram (DVH)
chemoradiation therapy (CRT)
esophageal cancer
hematologic toxicity (HT)
toxicity
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
12
6
2019
Statut:
ppublish
Résumé
Hematologic toxicity (HT) commonly occurs during chemoradiation therapy (CRT) for esophageal cancer. We sought to determine radiation doses that correlate with declines in blood counts due to vertebral body (VB) irradiation during CRT. We analyzed 53 esophageal cancer patients who were treated with weekly neoadjuvant carboplatin, paclitaxel and RT with weekly complete blood counts (CBC) available during treatment. HTs were graded according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Dose volume histogram (DVH) parameters of Vx, defined as percentage of entire bony vertebra (body, pedicles, laminae, processes) receiving at least x Gy of radiation, were collected for VB V A proportion of 32.1% of patients (n=17) developed grade 3 leukopenia and 5.7% (n=3) developed grade 4 leukopenia. VBV VBV
Sections du résumé
BACKGROUND
BACKGROUND
Hematologic toxicity (HT) commonly occurs during chemoradiation therapy (CRT) for esophageal cancer. We sought to determine radiation doses that correlate with declines in blood counts due to vertebral body (VB) irradiation during CRT.
METHODS
METHODS
We analyzed 53 esophageal cancer patients who were treated with weekly neoadjuvant carboplatin, paclitaxel and RT with weekly complete blood counts (CBC) available during treatment. HTs were graded according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Dose volume histogram (DVH) parameters of Vx, defined as percentage of entire bony vertebra (body, pedicles, laminae, processes) receiving at least x Gy of radiation, were collected for VB V
RESULTS
RESULTS
A proportion of 32.1% of patients (n=17) developed grade 3 leukopenia and 5.7% (n=3) developed grade 4 leukopenia. VBV
CONCLUSIONS
CONCLUSIONS
VBV
Identifiants
pubmed: 31183202
doi: 10.21037/jgo.2019.01.20
pii: jgo-10-03-513
pmc: PMC6534715
doi:
Types de publication
Journal Article
Langues
eng
Pagination
513-522Subventions
Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of Interest: Dr. Jabbour receives research funding from Merck and Nestle. The other authors have no conflicts of interest to declare.
Références
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):729-737
pubmed: 29280467
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39
pubmed: 7713791
Lancet Oncol. 2005 Sep;6(9):659-68
pubmed: 16129366
N Engl J Med. 1998 Dec 31;339(27):1979-84
pubmed: 9869669
Clin Lung Cancer. 2011 Jul;12(4):252-7
pubmed: 21726825
Lancet Oncol. 2014 Mar;15(3):305-14
pubmed: 24556041
J Leukoc Biol. 1992 Oct;52(4):433-40
pubmed: 1402391
World J Surg. 1987 Aug;11(4):426-32
pubmed: 3630187
Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):429-40
pubmed: 9226332
Surg Clin North Am. 2000 Apr;80(2):659-82; discussions 683-6
pubmed: 10836011
BMC Cancer. 2016 May 18;16:318
pubmed: 27194176
Cancer. 2001 Jun 1;91(11):2165-74
pubmed: 11391598
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1185-91
pubmed: 22270171
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1356-65
pubmed: 16757127
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1431-7
pubmed: 17996390
Arch Surg. 1992 Dec;127(12):1446-50
pubmed: 1365692
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):147-154
pubmed: 26700708
J Clin Oncol. 2008 Mar 1;26(7):1086-92
pubmed: 18309943
N Engl J Med. 2001 Sep 6;345(10):725-30
pubmed: 11547741
Cancer. 2011 Jul 1;117(13):3004-13
pubmed: 21264827
J Clin Oncol. 2021 Sep 1;39(25):2803-2815
pubmed: 34077237
Br J Radiol. 2016 Oct;89(1066):20160350
pubmed: 27556422
Am J Clin Oncol. 2018 Apr;41(4):362-366
pubmed: 27322697
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):128-135
pubmed: 28816138
Mol Cell Biol. 1993 Aug;13(8):4875-83
pubmed: 8393139
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):847-52
pubmed: 20472367
Cancer. 1973 Sep;32(3):699-711
pubmed: 4726969
Radiology. 1964 Dec;83:1084-8
pubmed: 14226812
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):769-78
pubmed: 14529783